# Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL

> **NCT03806179** · PHASE1 · COMPLETED · sponsor: **Nordic Nanovector** · enrollment: 7 (actual)

## Conditions studied

- Non Hodgkin Lymphoma
- Follicular Lymphoma
- Relapsed Follicular Lymphoma

## Interventions

- **DRUG:** 10 MBq/kg Betalutin
- **DRUG:** 15 MBq/kg Betalutin

## Key facts

- **NCT ID:** NCT03806179
- **Lead sponsor:** Nordic Nanovector
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-04
- **Primary completion:** 2022-08-08
- **Final completion:** 2022-08-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-12-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03806179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03806179, "Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03806179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*